(18 days)
No
The device description focuses on the physical components and materials of the embolic coils and delivery system, with no mention of software, algorithms, or data processing that would indicate AI/ML.
Yes
The device is described as an "implantable coil" system intended for "embolization" of various vascular abnormalities, which is a therapeutic intervention.
No
The device is an embolic coil system used for embolization, which is a treatment procedure, not a diagnostic one.
No
The device description clearly outlines physical components including implantable coils, a delivery pusher, a peel-away introducer sheath, and syringes, indicating it is a hardware-based medical device.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is for the embolization of intracranial aneurysms and other vascular abnormalities. This is a therapeutic procedure performed in vivo (within the body) to block blood flow.
- Device Description: The device description details an implantable coil and a delivery system. This is consistent with a device used for a surgical or interventional procedure, not for analyzing samples in vitro (outside the body).
- Lack of IVD Characteristics: The text does not mention any of the typical characteristics of an IVD, such as:
- Analyzing biological samples (blood, urine, tissue, etc.)
- Detecting or measuring substances in samples
- Providing diagnostic information based on sample analysis
- Reagents or test kits
The device is an implantable medical device used for a therapeutic intervention.
N/A
Intended Use / Indications for Use
The MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit are intended for embolization of those intracranial aneurysms that - because of their morphology, their location, or the patient's general medical condition - are considered by the treating neurosurgical team to be very high risk for management by traditional operative techniques or inoperable. The MCS and HES are also intended for embolization of other neuro-vascular abnormalities such as arteriovenous malformations and arteriovenous fistulae and for arterial and venous embolizations in the peripheral vasculature.
Product codes
HCG
Device Description
The MicroVention MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) consist of an implantable coil attached to a fluid injection delivery system called a Delivery Pusher. The coil is delivered on the Delivery Pusher through standard neurointerventional microcatheters. The Delivery Pusher consists of a variable stiffness tube with a retention sleeve that attaches the pusher to the implantable coil. A peel-away introducer sheath assists in the delivery of the coil into the microcatheter. The HydroLink Syringe Kit is packaged separately and includes a 1.0-cc syringe for system de-airing and a 0.25-cc and/or 0.5-cc syringe for coil detachment. An introducer needle is also included for use with the 0.25-cc or 0.5-cc syringe to fill the hub of the Delivery Pusher with contrast agent and eliminate any air.
The MicroPlex Coil System (MCS) is marketed in two basic coil configurations, complex and helical. The MCS-CC-2D and MCS-CC-1D are platinum complex coils that are used to establish the initial framework in the treatment of vascular abnormalities (e.g., intracranial aneurysms). The MCS-HC-R, MCS-HC-S and MCS-HC-SX are platinum helical coils that provide additional filling once the initial framework has been established by one or more complex coils. The MCS-CC-2D, MCS-CC-1D, MCS-HC-R and MCS-HC-S platinum coils were determined to be substantially equivalent on October 29, 2001 (reference K012145). The MCS-HC-SX platinum coils were determined to be substantially equivalent on July 9, 2002 (reference K021914). The complex and helical coils are provided in a number of diameters and lengths to meet the needs of the physician.
The MCS-HCP are platinum helical coils with an outer layer of a hydrophilic, acrylic polymer that also provides additional filling once the initial framework has been established by placement of one or more MCS platinum complex coils. The MCS-HCP coils were determined to be substantially equivalent on July 29, 2002 (reference K020434) and were originally included as part of the MicroPlex Coil System (MCS). In order to differentiate the platinum/polymer coils from the platinum coils, the system trade name has been changed to HydroCoil Embolic System (HES) and the coils are denoted as HES-HC-R.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Intracranial, neuro-vascular abnormalities (arteriovenous malformations and arteriovenous fistulae), peripheral vasculature.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Treating neurosurgical team
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance testing including tensile strength, coil detachment and simulated use demonstrated that the MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit has equivalent performance to the predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
K012145, K021914, K020434, K875196
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5950 Neurovascular embolization device.
(a)
Identification. A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral ateriovenous malformations. This does not include cyanoacrylates and other embolic agents, which act by polymerization or precipitation. Embolization devices used in other vascular applications are also not included in this classification, see § 870.3300.(b)
Classification. Class II (special controls.) The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Vascular and Neurovascular Embolization Devices.” For availability of this guidance document, see § 882.1(e).
0
Section 2 - Summary of Safety and Effectiveness
Company Information (1)
MicroVention, Inc. 72 Argonaut Aliso Viejo, CA 92656 Telephone: (949) 768-1184 Fax: (949) 768-0464 www.microvent.com
(2) Contact Information
Vincent Cutarelli Telephone: (949) 768-1184 ext. 105 Fax: (949) 768-0464 E-mail: vinc@microvent.com
(3) Device Name
| Trade/Proprietary Name: | MicroPlex™ Coil System (MCS) and
HydroCoil™ Embolic System (HES) with the
HydroLink™ Syringe Kit |
|-------------------------|--------------------------------------------------------------------------------------------------------|
| Common/Usual Name: | Embolization Coil |
| Classification Name: | Device, Artificial Embolization |
(4) Device Description
The MicroVention MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) consist of an implantable coil attached to a fluid injection delivery system called a Delivery Pusher. The coil is delivered on the Delivery Pusher through standard neurointerventional microcatheters. The Delivery Pusher consists of a variable stiffness tube with a retention sleeve that attaches the pusher to the implantable coil. A peel-away introducer sheath assists in the delivery of the coil into the microcatheter. The HydroLink Syringe Kit is packaged separately and includes a 1.0-cc syringe for system de-airing and a 0.25-cc and/or 0.5-cc syringe for coil detachment. An introducer needle is also included for use with the 0.25-cc or 0.5-cc syringe to fill the hub of the Delivery Pusher with contrast agent and eliminate any air.
The MicroPlex Coil System (MCS) is marketed in two basic coil configurations, complex and helical. The MCS-CC-2D and MCS-CC-1D are platinum complex coils that are used
1
to establish the initial framework in the treatment of vascular abnormalities (e.g., intracranial aneurysms). The MCS-HC-R, MCS-HC-S and MCS-HC-SX are platinum helical coils that provide additional filling once the initial framework has been established by one or more complex coils. The MCS-CC-2D, MCS-CC-1D, MCS-HC-R and MCS-HC-S platinum coils were determined to be substantially equivalent on October 29, 2001 (reference K012145). The MCS-HC-SX platinum coils were determined to be substantially equivalent on July 9, 2002 (reference K021914). The complex and helical coils are provided in a number of diameters and lengths to meet the needs of the physician.
The MCS-HCP are platinum helical coils with an outer layer of a hydrophilic, acrylic polymer that also provides additional filling once the initial framework has been established by placement of one or more MCS platinum complex coils. The MCS-HCP coils were determined to be substantially equivalent on July 29, 2002 (reference K020434) and were originally included as part of the MicroPlex Coil System (MCS). In order to differentiate the platinum/polymer coils from the platinum coils, the system trade name has been changed to HydroCoil Embolic System (HES) and the coils are denoted as HES-HC-R.
(5) Indications for Use
The MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit are intended for embolization of those intracranial aneurysms that - because of their morphology, their location, or the patient's general medical condition are considered by the treating neurosurgical team to be very high risk for management by traditional operative techniques or inoperable. The MCS and HES are also intended for embolization of other neuro-vascular abnormalities such as arteriovenous malformations and arteriovenous fistulae and for arterial and venous embolizations in the peripheral vasculature.
(6) Name of Predicate or Legally Marketed Device
MicroVention MicroPlex Coil System (MCS) - K012145 (October 29, 2001) MicroVention MicroPlex Coil System (MCS) - K021914 (July 9, 2002) MicroVention MicroPlex Coil System (MCS) - K020434 (July 29, 2002) Merit Medical Piston Syringe - K875196 (February 11, 1988)
(7) Technological Characteristics and Substantial Equivalence
The MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit is substantially equivalent to the MicroPlex Coil System (MCS) that was determined to be substantially equivalent per K012145, K021914 and K020434 and the Merit Medical Piston Syringe that was determined to be substantially equivalent per K875196. The operating principles, method of application, indications for use and technological characteristics are the same as the predicate devices.
2
KC22735
(8) Performance Data Summary
Performance testing including tensile strength, coil detachment and simulated use demonstrated that the MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit has equivalent performance to the predicate devices.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of three human profiles facing right, stacked on top of each other. The profiles are rendered in black and have a flowing, abstract design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the image.
6 2002 SEP
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Vincent Cutarelli Vice President, Regulatory Affairs, Quality Assurance and Clinical Affairs Microvention, Inc. 72 Argonaut Aliso Viejo, CA 92656
Re: K022735
Trade/Device Name: MicroPlex™ Coil System (MCS) and HydroCoil™ Embolic System with the HydroLink™ Syringe Kit.
Regulation Number: 882.5950 Regulation Name: Artificial Embolization Device Regulatory Class: III Product Code: HCG Dated: August 14, 2002 Received: August 19, 2002
Dear Mr. Cutarelli:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
4
Page 2 - Mr. Vincent Cutarelli
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Stupt Riwola
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications For Use
510(k) Number:
Device Name: MicroPlex™ Coil System (MCS) and HydroCoil™ Embolic System with the HydroLink™ Syringe Kit
Indications for Use: The MicroPlex Coil System (MCS) and HydroCoil Embolic System (HES) with the HydroLink Syringe Kit are intended for embolization of those intracranial aneurysms that - because of their morphology, their location, or the patient's general medical condition - are considered by the treating neurosurgical team to be very high risk for management by traditional operative techniques or inoperable. The MCS and HES are also intended for embolization of other neuro-vascular abnormalities such as arteriovenous malformations and arteriovenous fistulae and for arterial and venous embolizations in the peripheral vasculature.
Concurrence of CDRH, Office of Device Evaluation (ODE):
Stupt Roody
(Division Sign-Off) Division of General, Restorative and Neurological Devices
KO22735 510(k) Number ________________________________________________________________________________________________________________________________________________________________
Prescription Use: _ X_ (Per 21 CFR 801.109)